NANOVIRICIDES Enters Material Definitive Agreement

TL;DR

**NVIR just signed a big deal, but the details are still under wraps!**

AI Summary

NANOVIRICIDES, INC. (NVIR) filed an 8-K on February 16, 2024, reporting an "Entry into a Material Definitive Agreement" on February 12, 2024. The filing indicates a significant new agreement, though the specific details of the agreement, such as parties involved or financial terms, are not disclosed in this summary. The company's business address is 1 Controls Drive, Shelton, Connecticut 06484.

Why It Matters

This filing signals a potentially significant business development for NANOVIRICIDES, INC., which could impact its future operations, financial position, or strategic direction, even though the specific terms are not yet public.

Risk Assessment

Risk Level: medium — The risk is medium because a material definitive agreement has been entered into, but without specific details, the potential positive or negative impact on the company is unknown.

Key Players & Entities

• NANOVIRICIDES, INC. (company) — Registrant
• February 12, 2024 (date) — Date of earliest event reported
• February 16, 2024 (date) — Filing date
• 1 Controls Drive, Shelton, Connecticut 06484 (company) — Business address
• 001-36081 (company) — Commission File Number

FAQ

Key Financial Figures

• $0.00001 — Convertible Preferred Stock, par value $0.00001 per share (the "Milestone Shares") (as
• $1,500,000 — Million Five Hundred Thousand Dollars ($1,500,000) no later than five (5) business days a
• $2,000,000 — e Agreement); (iv) Two Million Dollars ($2,000,000), no later than five (5) business days
• $2,500,000 — Million Five Hundred Thousand Dollars ($2,500,000) no later than six (6) months after the
• $5,000,000 — (vii) either (A) Five Million Dollars ($5,000,000); or (B) Five Hundred Thousand (500,000

Filing Documents

• tm246547d1_8k.htm (8-K) — 36KB
• tm246547d1_ex10-2.htm (EX-10.2) — 56KB
• tm246547d1_ex10-3.htm (EX-10.3) — 135KB
• tm246547d1_ex10-4.htm (EX-10.4) — 15KB
• tm246547d1_ex10-5.htm (EX-10.5) — 5KB
• tm246547d1_ex10-5img001.jpg (GRAPHIC) — 6KB
• tm246547d1_ex10-5img002.jpg (GRAPHIC) — 2KB
• 0001104659-24-024973.txt ( ) — 480KB
• nnvc-20240212.xsd (EX-101.SCH) — 3KB
• nnvc-20240212_lab.xml (EX-101.LAB) — 33KB
• nnvc-20240212_pre.xml (EX-101.PRE) — 22KB
• tm246547d1_8k_htm.xml (XML) — 3KB

01

Item 1.01. Entry into a Material Definitive Agreement. Amendment to Coronavirus License Agreement As previously disclosed, on September 9, 2021, NanoViricides, Inc. (the "Company") entered into a License Agreement (the "License Agreement") with TheraCour Pharma, Inc. ("TheraCour") for an exclusive, worldwide license to the Company for further development with respect to TheraCour's research and development of services with respect to treatments for coronavirus derived human infections. Pursuant to the License Agreement, the Company is obligated to make payments to TheraCour upon TheraCour's achievement of certain milestones defined in the License Agreement ("Milestone Payments"). Pursuant to the License Agreement, the Company shall provide the following consideration to TheraCour based upon TheraCour's achievement of the Milestones: (i) One Hundred Thousand (100,000) shares of the Registrant's Series A Convertible Preferred Stock, par value $0.00001 per share (the "Milestone Shares") (as such number of shares may be adjusted for stock splits, combinations, divisions and other recapitalization events) no later than thirty (30) days after the achievement of Milestone 1 (as defined in the License Agreement); (ii) Fifty Thousand (50,000) Milestone Shares (as such number of shares may be adjusted for stock splits, combinations, divisions and other recapitalization events) no later than thirty (30) days after the achievement of Milestone 2 (as defined in the License Agreement); (iii) One Million Five Hundred Thousand Dollars ($1,500,000) no later than five (5) business days after the achievement of Milestone 3 (as defined in the License Agreement); (iv) Two Million Dollars ($2,000,000), no later than five (5) business days after the Commercialization, provided Milestone 3 is achieved; (v) Two Million Five Hundred Thousand Dollars ($2,500,000) no later than six (6) months after the Commercialization, provided Milestone 4 is achieved (as defined in the License Agreem

SIGNATURES

SIGNATURES PURSUANT TO THE REQUIREMENTS OF THE SECURITIES EXCHANGE ACT OF 1934, THE REGISTRANT HAS DULY CAUSED THIS REPORT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED THEREUNTO DULY AUTHORIZED. NANOVIRICIDES, INC. Date: February 16, 2024 By: /s/ Anil Diwan Name: Anil Diwan Title: Chairman, President

View Full Filing

View this 8-K filing on SEC EDGAR